These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 10215908)

  • 41. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine.
    Shults CW; Kimber T; Martin D
    Neuroreport; 1996 Jan; 7(2):627-31. PubMed ID: 8730845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
    Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
    J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.
    Hoffman AF; van Horne CG; Eken S; Hoffer BJ; Gerhardt GA
    Exp Neurol; 1997 Sep; 147(1):130-41. PubMed ID: 9294410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
    Natsume A; Mata M; Goss J; Huang S; Wolfe D; Oligino T; Glorioso J; Fink DJ
    Exp Neurol; 2001 Jun; 169(2):231-8. PubMed ID: 11358438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
    Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
    Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA; Su C
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
    Bentlage C; Nikkhah G; Cunningham MG; Björklund A
    Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
    Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
    Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
    Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
    Kobayashi S; Ogren SO; Hoffer BJ; Olson L
    Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts.
    Rosenblad C; Martinez-Serrano A; Björklund A
    Neuroscience; 1996 Dec; 75(4):979-85. PubMed ID: 8938733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy.
    Tseng JL; Bruhn SL; Zurn AD; Aebischer P
    Neuroreport; 1998 Jun; 9(8):1817-22. PubMed ID: 9665607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
    Kirik D; Rosenblad C; Björklund A
    Exp Neurol; 1998 Aug; 152(2):259-77. PubMed ID: 9710526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion.
    Kasanga EA; Owens CL; Cantu MA; Richard AD; Davis RW; McDivitt LM; Blancher B; Pruett BS; Tan C; Gajewski A; Manfredsson FP; Nejtek VA; Salvatore MF
    ACS Chem Neurosci; 2019 Oct; 10(10):4237-4249. PubMed ID: 31538765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.
    Tseng JL; Baetge EE; Zurn AD; Aebischer P
    J Neurosci; 1997 Jan; 17(1):325-33. PubMed ID: 8987758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
    Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.
    Björklund A; Rosenblad C; Winkler C; Kirik D
    Neurobiol Dis; 1997; 4(3-4):186-200. PubMed ID: 9361295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.